erlotinib hydrochloride has been researched along with encorafenib in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (encorafenib) | Trials (encorafenib) | Recent Studies (post-2010) (encorafenib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 149 | 21 | 144 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | encorafenib (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0021 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 2.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beijnen, JH; Rood, JJM; Rosing, H; Schellens, JHM; Sparidans, RW | 1 |
1 other study(ies) available for erlotinib hydrochloride and encorafenib
| Article | Year |
|---|---|
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.
Topics: Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Calibration; Carbamates; Chromatography, Liquid; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry | 2016 |